IDEAYA Biosciences, Inc. (IDYA) Dividend History

Company News

• Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity | DelveInsight

  The melanoma market is expected to surge between 2025-2034 due to increasing incidence, emerging therapies, heightened UV exposure, and diagnostic advancements. Several new therapies are in development, with potential to transform treatment options for melanoma patients.

  GlobeNewswire Inc.

  Featured Companies: BMY REPL
• Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga

  Kura Sushi USA reported weak Q3 results, missing analyst estimates. Several other companies, including LegalZoom.com, Stardust Power, 10x Genomics, IDEAYA Biosciences, and uniQure, also saw their shares decline in pre-market trading.

  Benzinga

  Featured Companies: KRUS LZ QURE TXG
• Company News for July 9, 2024 - July 9, 2024 - Zacks Investment Research

  Morphic Holding surged 75.1% on news of Eli Lilly's $3.2 billion acquisition. Ideaya Biosciences gained 15.3% after positive phase 2 trial results. Etsy fell 5.3% due to product sale restrictions. Intel jumped 6.2% following positive remarks from Melius Research.

  Zacks Investment Research

  Featured Companies: ETSY INTC
• BTIG lifts Ideaya Biosciences target to $62 on study data - Investing.com

  BTIG increased its price target on Ideaya Biosciences to $62 from $55, citing positive data from a Phase 2 study of the company's drug IDE397 as a monotherapy for treating certain cancers.

  Investing.com
• Why Ideaya Biosciences Stock Is Plummeting Today

  Ideaya stock is getting hit hard following a recent press release from the company.

  The Motley Fool